attenuates cardiac hypertrophy through modulation of cardiac Ca 2ϩ handling and calcineurin-NFAT signaling pathway.
This study aimed to explore the direct antihypertrophic role of PD in cultured neonatal rat ventricular myocytes (NRVMs) and its therapeutic effects against pressure overload (PO)-induced hypertrophic remodeling and heart failure. Furthermore, we investigated the mechanisms underlying the actions of PD. Treatment of NRVMs with phenylephrine for 72 h induced myocyte hypertrophy, where the cell surface area and protein levels of atrial natriuretic peptide and ␤-myosin heavy chain (␤-MHC) were significantly increased. The amplitude of systolic Ca 2ϩ transient was increased, and sarcoplasmic reticulum Ca 2ϩ recycling was prolonged. Concomitantly, calcineurin activity was increased and NFAT protein was imported into the nucleus. PD treatment restored Ca 2ϩ handling and inhibited calcineurin-NFAT signaling, thus attenuating the hypertrophic remodeling in NRVMs. PO-induced cardiac hypertrophy was produced by transverse aortic constriction (TAC) in C57BL/6 mice, where the left ventricular posterior wall thickness and heart-to-body weight ratio were significantly increased. The cardiac function was increased at 5 wk of TAC, but significantly decreased at 13 wk of TAC. The amplitude of Ca 2ϩ transient and calcineurin activity were increased at 5 wk of TAC. PD treatment largely abolished TAC-induced hypertrophic remodeling by inhibiting the Ca 2ϩ -calcineurin pathway. Surprisingly, PD did not inhibit myocyte contractility despite that the amplitude of Ca 2ϩ transient was decreased. The cardiac function remained intact at 13 wk of TAC. In conclusion, PD is beneficial against PO-induced cardiac hypertrophy and heart failure largely through inhibiting the Ca 2ϩ -calcineurin pathway without compromising cardiac contractility.
polydatin; hypertrophy; heart failure; calcium transient; calcineurin; NFAT; transverse aortic constriction CARDIAC HYPERTROPHY is an adaptive response most commonly to hypertension and an independent risk factor for the development of heart failure and more generally an increased morbidity and mortality (1, 18) . At the cellular level, enlargement of the cardiomyocyte involves multiple events, including gene transcription and protein translation/synthesis, which are regulated by multiple signaling cascades. Among them, enhancement of calcium-regulated signaling pathways plays a major role in the development of pathological cardiac hypertrophy (15, 26, 33 channel blockers, which have been confirmed to be therapeutically effective for the treatment of cardiac hypertrophy in many animal models (14, 29) . However, clinical blockade of LTCC has dubious benefit on cardiovascular mortality, despite that calcium channel antagonists induce regression of hypertrophy (19, 37) . Given the essential role of intracellular Ca 2ϩ in cardiac contraction, blockade of LTCC would decrease cardiac contractile function. Furthermore, blockade of noncardiac Ca 2ϩ channels induces side effects, including systemic hypotension, constipation, edema, etc. (7, 16) . All these shortcomings of LTCC antagonists counteract their beneficial effects on the treatment of cardiac hypertrophy. Thus new agents (drugs) that can suppress cardiac Ca 2ϩ signaling without causing the side effects are highly expected.
Polydatin (PD), a resveratrol glucoside with a 3,4=,5-trihydroxystilben-3-␤-D-mono-D-glucoside molecular structure, is a natural component extracted from the perennial herbage Polygonum cuspidatum Sieb. et Zucc (5, 10) . So far, there is only one study reporting that PD attenuated ventricular remodeling in vivo by inhibiting the activation of neurohormone (13) . Whether PD has a direct antihypertrophic effect and whether it modifies the heart failure process in vivo remain unknown. Recently, we found that PD modulated Ca 2ϩ handling and cardiac contractility. When acutely applied to isolated rat ventricular myocytes, PD significantly decreased LTCC current (I Ca,L ) and moderately decreased systolic Ca 2ϩ transient. Interestingly, PD slightly increased rather than decreasing cardiac contractility (8) . The findings in normal cardiomyocytes lead us to the hypothesis that PD suppresses hypertrophic stimuli-induced upregulation of Ca 2ϩ signaling and thus exerts a direct antihypertrophic effect, without compromising cardiac contractile function. If the hypothesis is true, combining with previous findings that PD did not reduce blood pressure and interfere with systemic hemodynamics in normal animals (30, 38) , it is rational to speculate that PD is a good candidate drug for the treatment of cardiac hypertrophy.
To test this hypothesis, we explored the therapeutic effect of PD on attenuation of hypertrophy in cultured neonatal rat ventricular myocytes stimulated with phenylephrine (PE) and in a pressure overload (PO)-induced hypertrophic mouse model. Furthermore, we investigated the effects of PD on cardiac Ca 2ϩ handling and contractility, as well as the Ca 2ϩ / calmodulin-activated calcineurin-nuclear factor of activated T cells (NFAT) signaling pathway, which has been shown to play a major role in the development of pathological cardiac hypertrophy (6, 24, 25, 34) . Here, we demonstrated that PD prohibited the development of cardiac hypertrophy in vitro as well as in vivo by inhibiting the Ca 2ϩ signal and calcineurin-NFAT signaling pathway. Culture of neonatal rat ventricular myocytes (NRVMs) and treatment protocol. Neonatal rat ventricular myocytes (NRVMs) were isolated from 2-day-old Sprague-Dawley rats and cultured as previously described (23) . In brief, hearts were obtained following decapitation and immersed in PBS and minced with scissors. The small pieces of heart tissue were digested with 0.25% trypsin-EDTA in PBS at 37°C. The isolated cells were put in fetal bovine serum (FBS) and pelleted by centrifugation at 1,000 rpm for 5 min. The pelleted cells were resuspended in DMEM containing 10% FBS, 1% penicillinstreptomycin, and then preplated for 30 min at 37°C to allow fibroblasts to adhere to the plate. The unadhered cells were pelleted again and resuspended in DMEM containing 10% FBS, 1% penicillinstreptomycin, and bromodeoxyuridine (1:100, to inhibit fibroblast growth), which were finally plated at a concentration of about 1 million cells per 35-mm plate. To produce hypertrophy, NRVMs were treated with 20 M phenylephrine (PE, Sigma) for 72 h after 24 h of serum starvation in the absence or presence of PD (25-75 M) . PD with a purity of 98.87% was kindly provided by Haiwang (Shenzhen, Guangdong, China).
METHODS

Animals
Measurement of cell surface area. The surface area of a single myocyte was measured with Image-Pro Plus Data Analysis Program (Media Cybernetics, Silver Spring, MD). Quantification of cell surface area was performed by measuring 50 random cells from three experiments, and the average value was used for analysis.
Calcineurin enzymatic assay. Calcineurin activity was determined in myocyte extracts using a colorimetric Calcineurin Cellular Activity Assay Kit following the manufacturer's instructions (Enzo Life Sciences) (21) . Calcineurin activity was determined as nanomoles phosphate released at 620 nm using a SpectraMax 5 (Molecular Devices, Sunnyvale, CA) plate reader.
Western blotting. Cell lysates were resolved in SDS polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). Nuclear protein extraction Biotechnology) was used as a loading control for ANP and calcineurin proteins, and LaminA/C as a loading control for NFAT3 nuclear protein.
Determination of ␤-MHC mRNA level. Total RNA was extracted using TRIZOL (Invitrogen) according to the manufacturer's instructions. The mRNA level of ␤-MHC was determined with reverse transcription-polymerase chain reaction (RT-PCR) with GAPDH as an internal control. PCR conditions to amplify ␤-MHC and GAPDH genes were as follows: denaturation at 94°C for 30 s, followed by annealing at 57°C for 30 s and elongation at 72°C for 1 min. Both genes were amplified for 35 cycles. The sequences of ␤-MHC primers were forward 5=-TCGTGGAGCGCGCAACAAC-3= and reverse 5=-TCAAAGGCTCCAGGTCTCAGGGCT-3=. The sequences of GAPDH primers were forward 5=-GCATGTCAGATCCACAA-CGG-3= and reverse 5=-GCATGTCAGATCCACAACGG-3=.
Transverse aortic constriction (TAC). C57BL/6 male mice (9 -10 wk, 18 -22 g) were randomly divided into four groups: sham and TAC with or without PD treatment, 10 in each group. The TAC model was produced as described previously (22) . In brief, the animal was endotracheally intubated under anesthesia with a mixture of pentobarbital sodium (50 mg/kg ip). The chest cavity was entered in the second intercostal space at the left upper sternal border, and the transverse aorta between the carotid arteries was isolated and constricted by a 7-0 silk suture ligature tied firmly against a 26-gauge needle. The latter was promptly removed to yield a constriction of 0.45 mm in diameter. Sham-operated mice underwent a similar surgical procedure without constriction of the aorta. PD was administered by oral gavage (50 mg·kg Ϫ1 ·day Ϫ1 ) 3 days after the surgery for a period of 9 wk.
Two-dimensional guided M-mode echocardiography. Two-dimensional (2-D) guided M-mode echocardiography was performed in anesthetized mice (with 1.5% isoflurane) using a Vevo 2100 system (VisualSonics, Toronto, Ontario, Canada). The heart was imaged in the 2-D mode in the parasternal short-axis view. From this view, the following parameters were measured: percentage of left ventricular (LV) fractional shortening (LVFS), LV ejection fraction (EF), LV internal dimensions at both diastole and systole (LVIDd and LVIDs, respectively), and LV posterior wall dimensions at both diastole and systole (LVPWd and LVPWs, respectively). All measurements were done from leading edge to leading edge according to the American Society of Echocardiography guidelines. The percentage of LVFS (%) was calculated as [(LVIDd Ϫ LVIDs)/LVIDd] ϫ 100, and EF (%) was calculated as [(LVIDd 2 Ϫ LVIDs 2 )/LVIDd 2 ] ϫ 100. Isolation of adult mouse ventricular myocytes. Ventricular myocytes were isolated from anesthetized C57BL/6 mice at 5 wk of operation as described previously (39) . Briefly, the heart was quickly removed from the chest and cleaned and flushed with a Ca 2ϩ free buffer containing (in mM) 120 NaCl, 5.4 KCl, 1.2 MgSO4, 1.2 NaH2PO4, 5.6 glucose, 20 NaHCO3, 10 2,3-butanedione monoxime (BDM; Sigma), and 5 taurine, 10 HEPES (pH ϭ 7.4), and perfused using a Langendorff apparatus. All solutions were bubbled with 100% O 2. The enzymatic digestion was initiated by adding collagenase type B (0.75 mg/ml; Worthington), and protease type XIV (0.02 mg/ml; Sigma) to the perfusion solution. When the heart became swollen and hard after 3 min of digestion, 50 M Ca 2ϩ was added to the enzyme solution and perfused for about 30 min. Following the perfusion procedure, the heart was minced into small chunks, and single cells were shaken loose from the heart tissue and stored in HEPES-buffered solution containing (mM) stimulation. Myocytes were superfused with HEPES-buffered external solution during the experiment.
Statistical analysis. All values were expressed as means Ϯ SE. Statistical analysis was performed by one-way analysis of variance (ANOVA) for multiple comparisons, followed by the Dunnett's test to evaluate the difference between two groups through the software of SPSS version 13.0. Values of P Ͻ 0.05 were considered statistically significant. 
RESULTS
PD inhibited phenylephrine (PE)-induced cardiomyocyte
hypertrophy. The in vitro cardiomyocyte hypertrophic model was successfully produced by treating the cultured neonatal rat ventricular myocytes (NRVMs) with 20 M PE for 3 days, in which the cell surface area was significantly increased by 56.5 Ϯ 6.2% (2,089 m 2 in PE-treated cells vs. 1,334 m 2 in control, P Ͻ 0.01, Fig. 1A) , and the protein levels of ANP and ␤-MHC were remarkably increased (Fig. 1, B and C) . PD treatment alone had no significant effects on the hypertrophic parameters observed. However, PD treatment (20 -75 M) dose-dependently reduced PE-induced hypertrophic remodeling. PD at the concentration of 50 M caused significant inhibition of PE-induced enlargement of cell size (Fig. 1A) . In parallel, the increased protein levels of ANP and ␤-MHC were largely reduced by 50 M PD treatment (Fig. 1, B and C) .
PD is an analog of trans-resveratrol. Figure 2A demonstrates the molecular structures of PD, trans-resveratrol and cisresveratrol. Previous studies have reported that resveratrol can significantly inhibit myocyte hypertrophy (9, 17) . We thus compared the effects of PD and trans-resveratrol (RV) on the hypertrophic parameters, including cell surface area and protein levels of ANP and ␤-MHC, in PE-stimulated NRVMs and found that the effect of PD (50 M) on suppression of myocyte hypertrophy was comparable to that of RV (50 M, Fig. 2 recycling, where the half time decay (T 50 ) of Ca 2ϩ transient was prolonged (Fig. 3C) . The result indicates that the SERCA function was impaired. Moreover, sustained PE stimulation increased the rise time of Ca 2ϩ transient, suggesting the synchrony of intracellular Ca 2ϩ release was impaired (Fig. 3D) . Consistent with the previous study, PD moderately decreased the amplitude of Ca 2ϩ transient in normal cells by 12.4%. However, PD treatment (50 M) significantly decreased the amplitude of Ca 2ϩ transient which was increased by PE stimulation (by 20.7%, Fig. 3, A and B) . Furthermore, PD treatment normalized the rise time and T 50 of Ca 2ϩ transient prolonged by PE stimulation, indicating the restoration of the synchrony of intracellular Ca 2ϩ release and SR Ca 2ϩ recycling (Fig. 3, C  and D) . The data collectively indicate that PD corrects abnormal Ca 2ϩ handling induced by long-term PE stimulation. PD suppressed PE-activated calcineurin-NFAT signaling pathway. It is well established that an increase in intracellular Ca 2ϩ activates calcineurin-NFAT signaling pathway, which plays a major role in the pathogenesis of cardiac hypertrophy. The above finding suggests that PE activates this hypertrophic pathway and PD may inhibit it. As anticipated, PE significantly increased calcineurin activity by 60.8 Ϯ 7.2% (P Ͻ 0.05) without significantly changing the protein expression (P Ͼ 0.05, Fig. 4, A and B) . Concomitantly, NFAT transferred into nuclear, whereby the nuclear NFAT protein level was significantly increased by 50.3 Ϯ 4.6% (P Ͻ 0.01) with PE stimulation (Fig. 4C) , but cytosolic protein level of NFAT was significantly decreased (Fig. 4D) . PD treatment (50 M) had no significant effect on calcineurin activity and NFAT nuclear protein level in control cells. In contrast, PD significantly reduced PE-induced upregulation of calcineurin activity and NFAT nuclear import (Fig. 4, B and C) . The results implicate that PD inhibits the activation of the calcineurin-NFAT signaling pathway, contributing to PE-induced myocyte hypertrophy.
To further confirm that PD attenuated myocyte hypertrophy through inhibition of the Ca 2ϩ -calcineurin signaling pathway, we cotreated PE-stimulated cells with PD and nifedipine (20 M) , the LTCC blocker, or FK506 (200 nM), the calcineurin inhibitor. The results show that nifedipine and FK506 treatment alone significantly inhibited PE-induced increase of cell size and ANP protein level (Fig. 4, E and F) , suggesting the important role of the Ca 2ϩ -activated calcineurin pathway in the pathogenesis of hypertrophic remodeling. Cotreating PE-stimulated cells with PD and nifedipine or FK506 only slightly increased the effect of PD on cell size and ANP protein level (Fig. 4, E and F) . The results further indicate the causal relationship between inhibition of Ca 2ϩ -calcineurin pathway and attenuation of myocyte hypertrophy by PD treatment.
It has been suggested that the NFAT pathway can be regulated by AMP-activated protein kinase (AMPK) (11, 20) . A previous study has demonstrated that resveratrol exerts antihypertrophic effects by activating AMPK, thus suppressing the NFAT pathway and protein synthesis and gene transcription (4) . To test whether this is the case for PD's action, we examined the levels of phosphorylated AMPK. We examined the effect of PD on the level of phosphorylated AMPK. The result shows that PD significantly increased the phosphorylation level of AMPK in cells with or without PE stimulation (Fig. 5, A and B) , suggesting that PD can suppress the NFAT pathway through activation of AMPK in addition to inhibition of Ca 2ϩ signaling.
PD inhibited pressure overload (PO)-induced cardiac hypertrophy in mice.
The in vitro data strongly suggest that PD can prevent the development of hypertrophy in vivo through the mechanisms indicated above. We thus investigated the effect of PD on PO-induced hypertrophy in mice. Cardiac structure and function were monitored for 13 wk (Fig. 6A) . Cardiac structure assessment involved measurement of the thickness of the left ventricular posterior wall (LVPW) and left ventricular internal dimension (LVID). Both systolic (LVPWs) and diastolic LVPW (LVPWd) were increased dramatically at 2 wk of TAC. The LVPWs was increased to a peak at 5 wk of TAC, and then decreased gradually. Despite this, the LVPW was still significantly larger than that in sham 13 wk after TAC (Fig. 6B) . The LVPWd was increased by 41.5 Ϯ 5.6%, 53.2 Ϯ 6.1%, 50.8 Ϯ 6.5%, and 48.7 Ϯ 6.5% at 2 wk, 5 wk, 8 wk and 13 wk of TAC compared with sham (Fig. 6C) . The LVIDs and LVIDd decreased significantly at wk of TAC and then increased gradually and significantly larger than control at 13 wk of TAC (Fig. 6, D and E) , suggesting that eccentric hypertrophy developed following the concentric hypertrophy. The hearts were isolated and the heart weight-to-body weight (HW/ BW) ratio was measured at 13 wk of TAC. Figure 7 , A and B, shows that the hearts were enlarged and the HW/BW ratio was significantly increased in mice subjected to TAC. There was no significant difference in BW in four groups (data not shown). The protein levels of ANP and ␤-MHC were accordingly increased in TAC mice (Fig. 7, C and D) .
As anticipated, PD treatment largely reversed the hypertrophic remodeling. The values of LVPWs and LVPWd were not significantly changed at 2 to 8 wk of TAC and were only slightly increased at 13 wk of TAC compared with sham (Fig.  6, A-C) . Meanwhile, PD treatment abolished TAC-induced alteration of LVIDs and LVIDd (Fig. 6, D and E) . The HW/BW ratio and the protein levels of ANP and ␤-MHC were consistently decreased by PD treatment (Fig. 7) . The data indicate that PD prevents the development of PO-induced hypertrophy.
PD improved PO-induced cardiac dysfunction. The cardiac systolic function was assessed by left ventricular fractional shortening (LVFS) and LV ejection fraction (EF). The LVFS and EF were significantly increased at 5 wk of TAC, but returned to normal at 8 wk of TAC and significantly lower than normal at 13 wk of TAC (P Ͻ 0.01, Fig. 6, F and  G) . With PD treatment, both EF (14.2 Ϯ 4.4%) and LVFS (16.1 Ϯ 2.5%) were moderately increased at 5 wk of TAC compared with sham (P Ͼ 0.05, Fig. 6, F and G) . The LVFS and EF were still maintained at relatively high levels at 8 wk of TAC and significantly higher than those without PD treatment (all P Ͻ 0.01). Both LVFS and EF were not significantly different from those in sham but significantly higher than those in TAC without PD treatment at 13 wk of TAC (Fig. 6, F and G) .
PD inhibited Ca 2ϩ -activated calcineurin-NFAT pathway in TAC mice. The above data suggest that compensatory concentric hypertrophy developed at 5 wk of TAC. We thus measured Ca 2ϩ signaling, calcineurin activity, and NFAT nuclear transport at this time point. Consistent with the enhancement of cardiac function (both EF and LVFS were increased), the amplitude of AP-elicited Ca 2ϩ transient and myocyte contractility in cardiomyocytes isolated from TAC mice were significantly increased (n ϭ 85 and n ϭ 80 for TAC group and sham group, respectively, P Ͻ 0.01 vs. sham). The T 50 of Ca 2ϩ transient was significantly increased in TAC mice (P Ͻ 0.01, Fig. 8D ), suggesting the impairment of SR Ca 2ϩ cycling in hypertrophic cardiomyocytes. In parallel with the alteration of Ca 2ϩ signaling, the calcineurin phosphatase activity was significantly increased and NFAT transferred into nuclear in TAC (P Ͻ 0.05, Fig. 8, E-H) . PD treatment corrected the abnormal Ca 2ϩ signaling, in which both the amplitude and T 50 of Ca 2ϩ transient were returned to normal (Fig. 8, A, B, and D) . The activation of calcineurin-NFAT pathway was concomitantly abolished by PD treatment (Fig.  8, E-H) . The results collectively indicate that PD prevented the pathogenesis of PO-induced hypertrophy by inhibition of the Ca 2ϩ -activated calcineurin signaling pathway. Of note, the cardiac contractility in isolated ventricular myocytes from PD-treated TAC mice was still significantly higher than that in sham (Fig. 8C) , despite that the amplitude of AP-elicited Ca 2ϩ transient was not significantly different from that in sham. The increase in cellular contractility in single cardiomyocyte is consistent with the increase of LVFS and EF in PD-treated TAC mice (Fig. 6,  F and G) .
DISCUSSION
In this study, we monitored the effects of sustained longterm PO on cardiac structure and function and demonstrated a typical development of the heart from "compensatory" cardiac hypertrophy to "decompensatory" heart failure. An important finding in this study was that PD has a potent therapeutic effect on preventing the development of cardiac hypertrophy and deterioration to heart failure upon sustained PO stimulation. Furthermore, we found that PD dose-dependently prevented hypertrophic remodeling in cultured cardiomyocytes in vitro.
The results indicate that PD can target directly on cardiomyocytes to prevent the pathogenesis of hypertrophy. It is well established that Ca 2ϩ -regulated signaling pathways contribute to the pathogenesis of cardiac hypertrophy. For gene transcription, the Ca 2ϩ /calmodulin (CaM)-activated calcineurin-NFAT signaling pathway has been shown to play a major role in the development of pathological cardiac hypertrophy. Upon dephosphorylation by calcineurin, NFAT translocates to the nucleus of the cardiomyocyte where it mediates the transcription of numerous targets involved in hypertrophic growth (27, 32) . In this study, we found that calcineurin activity was upregulated and the nuclear NFAT protein level was increased in both PE-induced hypertrophic cardiomyocytes and in POinduced hypertrophic heart. In accordance with the activation of the calcineurin-NFAT signaling pathway, the amplitude of systolic Ca 2ϩ transient in cardiomyocytes was significantly increased. Meanwhile, the SR Ca 2ϩ recycling indicated by T 50 of Ca 2ϩ transient was slowed, indicating the disturbance of intracellular Ca 2ϩ homeostasis. Of importance, blockage of LTCC with nifedipine or inhibition of calcineurin activity with FK506 significantly suppressed PE-induced hypertrophic remodeling. This in vitro and in vivo evidence is in support of the key role of the Ca 2ϩ -activated calcineurin-NFAT signaling pathway in the development of cardiac hypertrophy.
Since upregulation of Ca 2ϩ signaling increases cardiac contractile function, which represents "compensatory" response projected to normalize wall stress and facilitates systolic performance, inhibition of Ca 2ϩ signaling with a LTCC blocker suppresses cardiac function and is not beneficial for the treatment of cardiac hypertrophy. In this study, we found that PD inhibited the calcineurin-NFAT signaling pathway. PD attenuated the development of cardiac hypertrophy both in vitro and in vivo. Furthermore, we found that this effect was mediated by inhibition of cardiac Ca 2ϩ handling, for PD completely abolished the increase of the amplitude of systolic Ca 2ϩ transient in cultured cardiomyocytes upon PE stimulation and in single cardiomyocytes isolated from hearts challenged with PO. Of particular interest, PD, unlike Ca 2ϩ -channel blockers, did not impair cardiac contractile function, despite that PD significantly decreased the amplitude of systolic Ca 2ϩ transients. Moreover, PD restored the impaired SR Ca 2ϩ recycling, which has been well documented, inducing cardiac dysfunction in heart failure by causing Ca 2ϩ overload during diastole. The unique regulations of PD on Ca 2ϩ handling and contractility in cardiomyocytes indicate that PD is superior to Ca 2ϩ -channel blockers on the treatment of cardiac hypertrophy.
Previous study has demonstrated that PD can also inhibit calcineurin activity. However, the causal link between the modulations of Ca 2ϩ signaling and calcineurin activity remains unknown. This present study reveals for the first time that PD modulation of intracellular Ca 2ϩ signaling is an important mechanism for PD inhibition of the activation of calcineurin-NFAT pathway, which may also be the case for the action of resveratrol.
The ability of PD to inhibit Ca 2ϩ signaling and subsequent calcineurin-NFAT signaling pathway may represent its pivotal effect in terms of attenuating the hypertrophic response. However, other mechanisms should also participate in the antihypertrophic effect of PD. In this study, we found that PD significantly increased AMPK activity in PE-stimulated cells, suggesting the involvement of this signal pathway in PD suppression of cardiac hypertrophy.
In this study, we found PD only mildly regulated cardiac Ca 2ϩ handling under physiological conditions, whereas it had strong suppression on abnormal Ca 2ϩ handling under pathological hypertrophic stimuli. Reports have confirmed safety of PD administration orally up to 100 mg/kg in animals (13, 35, 36) , and PD has now obtained permission from the Chinese Food and Drug Administration for phase II clinical trials for the treatment of severe hemorrhagic shock. All the evidence highlights the beneficial role of PD in the treatment of cardiac hypertrophy and heart failure.
In conclusion, our present study demonstrated that PD had a potent antihypertrophic effect in PE-induced cardiomyocyte hypertrophy and PO-induced cardiac hypertrophy. Furthermore, PD prevented the development of cardiac contractile dysfunction under sustained PO. The beneficial effects of PD were largely attributed to its modulation of Ca 2ϩ handling and inhibition of subsequent activation of the calcineurin-NFAT signaling pathway without compromising cardiac contractile function.
